ArticleBMC rheumatology2025
Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective study.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-MDA5 dermatomyositis (anti-MDA5 DM) is a rare but severe subtype of dermatomyositis associated with high mortality. This study aimed to describe clinical characteristics and identify variables associated with rapidly progressive interstitial lung disease (RP-ILD) and mortality among affected patients.
methodsPatients diagnosed with anti-MDA5 DM between January 2013 and October 2022 were included. Demographics, clinical manifestations, and laboratory data were collected. Univariable Cox proportional hazard regression was used to assess mortality predictors, while logistic regression models identified factors associated with RP-ILD.
resultsAmong 26 patients (mean age, 56.6 ± 15.1 years, 7 men), the most common clinical manifestation was Gottrón’s papules (80.8%), followed by ILD (73.1%), periungual erythema (69.2%), heliotrope rash (61.5%), V-sign (42.3%), arthritis (42.3%), weakness (38.5%), shawl sign (34.6%), mechanic’s hand (34.6%), and Raynaud’s phenomenon (19.2%). Among 19 ILD patients, 9 (47.4%) developed RP-ILD, and seven patients died over a median follow-up of 1.5 years. The overall mortality rate in this cohort was 26.9%, with 77.8% having RP-ILD. Mortality was associated with male sex (HR, 7.7; 95% CI, 1.49–39.9; P = 0.02) and RP-ILD, which had a risk difference of 77.8 (95% CI 50.6-104.9%; P = 0.001). Arthritis (P = 0.01) and ANA positivity (P = 0.03) were associated with reduced risk of RP-ILD. Patients with RP-ILD tended to receive aggressive treatments, including triple therapy regimens (55.6%), which consisted of a combination of intravenous methylprednisolone and intravenous cyclophosphamide with either rituximab or a calcineurin inhibitor. Additional treatments included intravenous immunoglobulin (22.2%) and plasma exchange (33.3%).
conclusionAnti-MDA5 DM was associated with a high prevalence of ILD, particularly RP-ILD, contributing to increased mortality, underscoring the need for early identification of high-risk patients and personalized management. TAKE-HOME MESSAGE: Male sex was a key predictor of RP-ILD and poor prognosis in anti-MDA5 dermatomyositis patients. Conversely, arthritis and ANA positivity might be associated with a lower risk of RP-ILD. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.